beta2
-
Australia’s Caution Reflected in LABA Debate
The US Food and Drug Administration (FDA) has announced a requirement for product labeling to warn that long-acting beta2-agonists (LABAs) should not be used alone for the treatment of asthma, but only in combination with a corticosteroid. These chan…
beta2 | 03 March 2010
